期刊档案 · 医学-医学:研究与实验
Advances in Clinical and Experimental Medicine
ISSN 1230-025X · eISSN 2451-2680 · Wroclaw University of Medicine · POLAND · Monthly · 创刊 1992
Advances in Clinical and Experimental Medicine 中科院 医学 4区(2025 年升级版),影响因子 2.46,订阅期刊,收取 APC,金额未公布,投稿社区反馈审稿6–12 周,录用比例容易(社区反馈),年发文 92 篇,SCIE、Scopus 收录。
研究范围
研究范围与定位
Advances in Clinical and Experimental Medicine (Adv Clin Exp Med) is an international, peer-reviewed journal that highlights the full translational pathway of biomedical research – from laboratory discoveries (“bench”), through clinical application (“bedside”), to real-world practice and policy (“implementation”). The journal welcomes original research articles, reviews/meta-analyses, clinical recommendations/guidelines, research-in-progress reports, research letters, and study protocols authored by recognized experts in clinical and experimental medicine. The journal does not publish case studies, case series, and bibliometric studies. By embracing this translational continuum, Adv Clin Exp Med serves as a platform for studies that not only advance scientific knowledge but also demonstrate clear potential to improve patient outcomes and healthcare systems. We particularly value contributions that bridge gaps between experimental insights, clinical trials, and the implementation of evidence-based practices in diverse medical settings, especially those developed by international, multi-center research teams. Advances in Clinical and Experimental Medicine is a multidisciplinary journal positioned at the interface of general and internal medicine, clinical research, and real-world implementation in healthcare systems.
摘自期刊官网 Aims & Scope
研究方向(LetPub):医学-医学:研究与实验
主编 Donata Kurpas出版商官网
编委会国家分布:未见中国大陆编委;主要国家 波兰 11(共 11 位编委标注了国家) 编委会 ↗出版商官网 ·
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表( 2025年3月升级版)医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 医学:研究与实验MEDICINE, RESEARCH & EXPERIMENTAL | 4 区 |
Top 期刊:否综述期刊:否
《新锐期刊分区表》( 2026年3月发布)医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 医学:研究与实验MEDICINE, RESEARCH & EXPERIMENTAL | 4 区 |
Top 期刊:否综述期刊:未标注
期刊分区表( 2023年12月旧的升级版)医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 医学:研究与实验MEDICINE, RESEARCH & EXPERIMENTAL | 4 区 |
Top 期刊:否综述期刊:否
数据库收录
SCIEScopusLetPub
国际期刊预警名单:各版本均未列入LetPub
期刊官网自述收录
Web of ScienceMEDLINEPubMed出版商官网
其他:Index Copernicus、Journal Impact Factor (JIF 2025) – 2.5、Journal Citation Indicator (JCI 2025) – 0.40、Index Copernicus Value (ICV 2024) – 161.00、MNiSW – 70 pts
期刊官网列出的收录清单,未与各数据库逐一核对;Web of Science 各子库以上方记录为准。
不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值;投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子
- 2.46LetPub ·
- 影响因子(出版商公布)
- 2.5出版商官网 ·
- 五年影响因子(出版商公布) 2025
- 2.3出版商官网 ·
- CiteScore 2026-06
- 4.2LetPub ·
- CiteScore(出版商公布) 2025
- 4.2出版商官网 ·
- SJR 2026-06
- 0.6LetPub ·
- SJR(出版商公布)
- 0.6出版商官网 ·
- SNIP 2026-06
- 0.66LetPub ·
- 自引率
- 8%LetPub ·
- Gold OA 文章占比
- 99.28%LetPub ·
发文规模
- 年文章数
- 92LetPub ·
- 年发文量(出版商公布)
- 70出版商官网 ·
不同来源的统计口径与观测时间不同,页面保留各来源原值;“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
- 平均审稿速度(社区反馈)
- 较慢,6-12周LetPub ·
- 平均录用比例(社区反馈)
- 容易LetPub ·
- 评审方式
- 单盲同行评审,至少 3 位审稿人出版商官网 · 模型提取
社区反馈来自投稿者样本,置信度 0.5,不代表期刊承诺;“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
订阅期刊,文章需订阅或购买阅读,通常不收取版面费。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| 出版商官网 | EUR 1,600 / EUR 990 / EUR 700 / EUR 350 | — | — |
费用以期刊官网为准;不同来源的观测时间可能不同,页面保留各来源原值,不做平均。
投稿要求
文章类型与投稿政策(官网)
投稿准备要点8 项,摘自作者指南
- 摘要
- 200–300 词
- 关键词
- ≥ 3 个
- 正文篇幅
- ≤ 7,000 词
- 参考文献格式
- AMA 格式
- 推荐审稿人
- 必须提供
- 图文摘要
- 必须提供
- 投稿信(Cover letter)
- 必须提供
- 不接收
- case reports
接收的文章类型20 种,含篇幅限制
- clinical recommendations/guidelinesThe journal welcomes original research articles, reviews/meta-analyses, clinical recommendations/guidelines, research-in-progress reports, research letters, and…未说明篇幅
- clinical recommendations/guidelines/scientific statementsClinical recommendations/guidelines/scientific statements未说明篇幅
- commentaryManuscripts may be considered for publication in the following sections: Original papers – including experimental research Reviews Meta-Analyses Research-in-Pro…正文 ≤ 1,500 词
- editorialManuscripts may be considered for publication in the following sections: Original papers – including experimental research Reviews Meta-Analyses Research-in-Pro…未说明篇幅
- editorial commentariesEditorial commentaries (by invitation only)未说明篇幅
- editorialsEditorials (by invitation only)未说明篇幅
- letterManuscripts may be considered for publication in the following sections: Original papers – including experimental research Reviews Meta-Analyses Research-in-Pro…正文 ≤ 7,000 词
- meta-analysesMeta-Analyses未说明篇幅
- meta-analysisManuscripts may be considered for publication in the following sections: Original papers – including experimental research Reviews Meta-Analyses Research-in-Pro…未说明篇幅
- original paperManuscripts may be considered for publication in the following sections: Original papers – including experimental research Reviews Meta-Analyses Research-in-Pro…正文 ≤ 1,500 词
- original papersOriginal papers – including experimental research未说明篇幅
- original research articlesThe journal welcomes original research articles, reviews/meta-analyses, clinical recommendations/guidelines, research-in-progress reports, research letters, and…未说明篇幅
- protocolManuscripts may be considered for publication in the following sections: Original papers – including experimental research Reviews Meta-Analyses Research-in-Pro…未说明篇幅
- research lettersResearch letters未说明篇幅
- research-in-progressResearch-in-Progress未说明篇幅
- research-in-progress reportsThe journal welcomes original research articles, reviews/meta-analyses, clinical recommendations/guidelines, research-in-progress reports, research letters, and…未说明篇幅
- reviewManuscripts may be considered for publication in the following sections: Original papers – including experimental research Reviews Meta-Analyses Research-in-Pro…未说明篇幅
- reviewsReviews未说明篇幅
- reviews/meta-analysesThe journal welcomes original research articles, reviews/meta-analyses, clinical recommendations/guidelines, research-in-progress reports, research letters, and…未说明篇幅
- study protocolsStudy Protocols未说明篇幅
官网政策摘录AI 使用、作者资格、利益冲突、数据可用性、出版伦理、许可与版权、同行评审、预印本
- AI 使用 Authorship and AI tools – COPE position statement
该期刊政策指出,人工智能工具(如ChatGPT或大型语言模型)不能被列为论文作者,因为它们无法满足作者资格要求,不能对提交的工作承担责任,也不能作为法律实体声明利益冲突或管理版权与许可协议。 模型中文摘要
The use of artificial intelligence (AI) tools, such as ChatGPT or Large Language Models, in research publications is expanding rapidly. COPE joins organisations, such as WAME and the JAMA Network, among others, to state that AI tools cannot be listed as an author of a paper. AI tools cannot meet the requirements for authorship, as they cannot take responsibility for the submitted work. As non-lega…
原文 ↗出版商官网 ·- 作者资格 Authorship
该期刊政策规定,论文正文中不得出现任何可识别作者身份的信息(尤其是作者姓名),所有做出重要贡献的作者应列为共同作者,并在投稿系统中按A至F六项标准(A研究构思与设计、B数据收集与/或整理、C数据分析与解释、D撰写文章、E对文章的批判性审阅、F最终批准)披露其作者贡献。 模型中文摘要
No information allowing for authors' identification, in particular authors' names, should appear anywhere in the main body of the paper. All Authors who have made significant contributions should be listed as co-authors, and their authorship should be disclosed in the Editorial System under the following list: A – research concept and design; B – collection and/or assembly of data; C – data analys…
原文 ↗出版商官网 ·- 利益冲突 Conflict of interest
该期刊政策要求,任何利益冲突应在投稿时通过编辑系统投稿流程中的专门部分报告,而非写在致谢部分或论文正文中,且所有作者须在投稿前提供披露信息,以纳入“利益冲突”声明。 模型中文摘要
Any conflict of interest should be reported while submitting the manuscript in a dedicated section of the submission procedure in our Editorial System, not in the Acknowledgements section or in the paper itself. All authors must provide disclosures before submission for inclusion in the “Conflict of Interest” statement. A conflict of interest exists when one’s professional judgment about the execu…
原文 ↗出版商官网 ·- 数据可用性 Policy concerning data sharing
该期刊政策要求,所有原创论文的作者在向期刊投稿时,须将复制研究结果所需的全部数据无限制地公开(相关信息须在投稿时登记于编辑系统),并将底层数据及相关元数据存入适当的公共数据仓库(除非已作为投稿文章的一部分提供)。 模型中文摘要
Adv Clin Exp Med requires the Authors of all original papers to make all data necessary to replicate their study's results publicly available without restriction when the paper is submitted to the journal (relevant information must be registered in the Editorial System at the time of submission). All the data and related metadata underlying the reported findings should be deposited in appropriate …
原文 ↗出版商官网 ·- 出版伦理 If ethical approval applies, its number is included in the text.
该期刊政策规定,缩略语应在正文中加以解释,而不是单独列成清单。 模型中文摘要
Abbreviations explained in the text, not on a separate list.
原文 ↗出版商官网 ·- 许可与版权 Our copyright declaration
该期刊政策要求作者声明:他们是该科学作品/出版物的版权持有人,有权处置版权以与弗罗茨瓦夫医科大学签订许可/出版协议,作品由其独立创作且不侵犯第三方权利;若因作者声明不符导致第三方对弗罗茨瓦夫医科大学提出索赔,作者须立即全额赔偿由此产生的全部损害、成本和费用。 模型中文摘要
The Author/Author(s) declare that: a) they are copyright holders of the scientific work/publication; b) they are entitled to dispose of copyright for the concluded license/publishing agreement with the Wroclaw Medical University; c) they created the work/publication on their own; d) the work/publication does not violate the rights of third parties. If a third party files a claim against Wroclaw Me…
原文 ↗出版商官网 ·- 同行评审
该期刊政策声明,《临床与实验医学进展》不接受病例报告。 模型中文摘要
Adv Clin Exp Med does not accept case reports.
原文 ↗出版商官网 ·- 预印本 Policy regarding preprints
该期刊政策表示,期刊支持并鼓励在非营利预印本服务器(如BioRxiv、MedRxiv、ResearchSquare或Authorea)以及作者个人或机构网站上发布稿件预印本,发布预印本不被视为提前发表,稿件仍可按常规流程进入该期刊的同行评审。 模型中文摘要
Adv Clin Exp Med endorses and encourages the posting of manuscript preprints on non-profit preprint servers such as BioRxiv, MedRxiv, ResearchSquare, or Authorea, as well as on authors’ or institutional websites. Posting preprints is not considered a prior publication, and the manuscript can enter peer review at Adv Clin Exp Med following the regular procedure. Preprints are defined as an author’s…
原文 ↗出版商官网 ·
摘录来自期刊官网页面,仅保留原文片段;“模型摘要”由 Workers AI 生成并经原文校验,以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Wroclaw University of Medicine
- 出版国家或地区
- POLAND
- 出版语言
- English
- 出版周期
- Monthly
- 创刊年份
- 1992
- ISSN
- 1230-025X
- 电子版 ISSN
- 2451-2680
- 官方链接
- 期刊主页 ↗LetPub
- 投稿系统 ↗LetPub
- 作者指南 ↗LetPub
- 专刊 / 特刊征稿 ↗出版商官网
常见问题
关于 Advances in Clinical and Experimental Medicine 的常见问题
Advances in Clinical and Experimental Medicine 是中科院几区期刊?
2025 年升级版分区表中,Advances in Clinical and Experimental Medicine 为医学 4区,小类 医学:研究与实验 4 区。2026 年新锐版分区表中为医学 4区。不同版本与大小类分区不能混用。
Advances in Clinical and Experimental Medicine 的影响因子是多少?
LetPub 汇总的最新公布影响因子为 2.46,CiteScore 为 4.2。
Advances in Clinical and Experimental Medicine 的审稿周期多长?
投稿社区反馈的平均审稿速度为6–12 周,平均录用比例反馈为“容易”。文章统计只含被录用的稿件,出版商数据口径以官网为准,社区反馈来自投稿者样本,均不代表期刊承诺。
Advances in Clinical and Experimental Medicine 的投稿格式要求是什么?
据期刊作者指南:摘要:200–300 词;关键词:≥ 3 个;正文篇幅:≤ 7,000 词;参考文献格式:AMA 格式;推荐审稿人:必须提供;图文摘要:必须提供;投稿信:必须提供。以上由模型从作者指南提取并逐项与原文核对,投稿前请以官网最新版本为准。
Advances in Clinical and Experimental Medicine 的编委会里有中国学者吗?
期刊官网编委会页面上标注了国家的 11 位编委中,没有中国大陆学者;人数最多的国家是 波兰(11 位)。统计按编委会页面列出的机构国家计,仅供参考。
Advances in Clinical and Experimental Medicine 被哪些数据库收录?
据 LetPub 与 DOAJ 记录,Advances in Clinical and Experimental Medicine 被 SCIE、Scopus 收录。期刊官网自述还被 Web of Science、MEDLINE、PubMed 收录,该清单未与各数据库逐一核对。
Advances in Clinical and Experimental Medicine 是开放获取期刊吗?版面费多少?
Advances in Clinical and Experimental Medicine 为订阅期刊。收取 APC,金额未公布。
来源与更新
本页事实来自 LetPub、出版商官网;每个数字旁标注来源与观测日期,冲突数据保留各来源原值。LetPub 原始详情页:查看 ↗(2026-08-26 归档)。最近更新:。